To the Editor:

Alberici *et al.*[@bib1] proposed in a recent review some therapeutic approaches for patients with end-stage renal disease and infected with coronavirus disease 2019 (COVID-19). They notably suggest the use of steroids during the inflammatory phase of the disease, even if their efficacy is currently being debated.[@bib2]^,^[@bib3]

We report the outcome of 9 patients with end-stage renal disease (7 of whom were undergoing chronic hemodialysis), admitted in our hospital for a rapidly worsening COVID-19 pneumonia (clinical characteristics are available in [Supplementary Table S1](#appsec1){ref-type="sec"}). A short steroids therapy (hydrocortisone hemisuccinate 200 mg per day for 5 days) was administrated when the oxygen flow was increased up to 3 L/min to maintain a pulse oximetry ≥95%. A moderate dose of steroids has been chosen to limit side effects, in particular infections. Clinical settings rapidly improved in 8 patients, with a significant drop in oxygen flow within 24 hours (median oxygen flow, 5 L/min at steroids initiation down to 3.3 L/min at day 1; *P* = 0.034 \[Wilcoxon matched pairs signed rank test\]; [Figure 1](#fig1){ref-type="fig"}). To date, oxygen was discontinued in 7 patients (median delay after steroids initiation, 4.5 days). The latter patient, a 30-year-old woman with severe obesity and chronic hemodialysis, needed invasive ventilation 24 hours after steroids initiation. The outcome was finally favorable and the patient was extubated 18 days after her admission to the intensive unit care.Figure 1Evolution of oxygen flow over time. D0, day of initiation of corticosteroids.

These are only the results of a small observational study and no definitive conclusion can be drawn from this report, but the quick improvement suggests that short steroids therapy could be a safe therapeutic option, especially in hemodialysis patients, who have a high risk of severe presentation.[@bib4]
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**Table S1.** Clinical characteristics of patients at admission and at the beginning of corticotherapy.
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